Phototoxic pathway

Results from a nationwide study of long-term treatment with voriconazole

Results from a nationwide study in France looking at 18 case reports worldwide and three retrospective studies suggest that long-term treatment with voriconazole is suspected to induce cutaneous squamous cell carcinoma (SCC).

Voriconazole is indicated for serious fungal infections. Side-effects include phototoxicity, and some reports link it to aggressive SCCs of the skin.

Doctors in France were asked to identify voriconazole recipients who had benign and malignant skin diseases. Nineteen SCCs were reported. Among these were 15 with high likelihood of being attributable to voriconazole.

In 14 of the 17 patients, SCCs were preceded by acute phototoxicity during the first year after voriconazole therapy and this progressed to actinic keratoses of the same sun-exposed skin in the second or third year, followed by SCC during the third year or later.

There is an apparent progression from phototoxic erythema to cutaneous pre-malignancies and cancers, so patients with signs of phototoxicity should be followed closely for skin cancers by a dermatologist. Discontinuation of voriconazole should be strongly considered in those patients who experience phototoxicity.

Epaulard O, Villier C, Ravaud P et al. Clin Infect Dis 2013; 57: e182


Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

1.5 CPD credits: Nails: Management of patients with onychomycosis

1.5 CPD credits: Nails: Management of patients with onychomycosis

New treatment modalities are offering promising results....

Nails: Diagnosis and therapy in fungal nail infection

Nails: Diagnosis and therapy in fungal nail infection

Fungal infections more commonly affect the toenails...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases